Storia in 2 fonti

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

Raccontata da

endpoints.news

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 g fa

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

originale

endpoints.news4 g fa

Treeline to go public via reverse merger with Standard BioTools

Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.

Leggi questa versione → originale

Timeline cronologica

lunedì 8 giugno 2026·endpoints.news
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.
martedì 9 giugno 2026·biopharmadive.com
Stealthy startup Treeline plans a reverse merger
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.